Pyrazinamide USP Antituberculosis Drug from Japan
Pyrazinamide, a pyrazine carboxamide derivative, is explicitly listed in HTS 2933.99.4200 as an anti-infective pharmaceutical. This first-line tuberculosis treatment is imported as pure USP powder for tablet manufacturing. Its aromatic heterocyclic structure with nitrogen hetero-atoms defines its Chapter 29 classification.
Duty Rate — Japan → United States
27.5%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.4912.5%Except for products described in headings 9903.05.85–9903.05.92, articles the product of Japan, with an ad valorem (or ad valorem equivalent) rate of duty under column 1 less than 12.5 percent, as provided for in U.S. note 52 to this subchapter
Import Tips
• Require DMF (Drug Master File) and bioequivalence data for API imports into US tablet production
• TB drugs face heightened FDA scrutiny; ensure GMP certification from manufacturing facility
• Confirm crystal form (polymorph) matches USP monograph to avoid reclassification issues